- Revenue increases 27% YoY to $4.9 million
- Veterinary vaccines totaled $0.2 million, up 58% YoY
- Veterinary medicines totaled $3.2 million, up 23% YoY
- Feed additives totaled $0.2 million, up 29% YoY
- Micro-organism products totaled $1.2 million, up 35% YoY
- Gross margin of 53% for the first three months of fiscal 2010 and compared to 49% for the three months ended March 31, 2009
- GAAP net income $1.1 million or $0.15 per fully diluted, compared with $1.1 million or $0.29 per fully diluted share in the year ago period
- Fiscal 2010 top line revenue guidance range increased to $45.5 million to $47.5 million from $44.0 million to $46.0 million
Gross profit for first quarter 2010 was $2.6 million, up 37% from first quarter 2009. Gross margin for the period was 53%, in line with historical year over year comparables. Operating expenses for first quarter 2009 were $0.8 million, or 17% of total revenue, compared with $0.6 million or 17% of total revenue in the year ago period. Research and development (R&D) costs were $0.04 million, or less than 1% of revenue in first quarter 2010, down from $0.1 million, or 3% of revenue during first quarter 2009. Most of the current research projects are in the later phases of development focusing on applications and documentation without the significant outlays related to the earlier phases of the projects when large scale testing was required. Selling expenses totaled $0.2 million, or 3% of revenue, for first quarter 2010, compared with $0.2 million, or 6% of revenue, in first quarter 2009. General and administrative expenses were $0.6 million, or 13% of revenue, in first quarter 2010, compared with $0.3 million, or 8% of revenue, in first quarter 2009. Operating income increased by 41% year over year to $1.7 million in the first quarter of fiscal year 2010, compared with $1.2 million in the same quarter a year ago, and operating margin increased to 36% from 32% in the same period a year ago. Net income for the first quarter of 2010 was $1.1 million, or $0.15 per fully diluted share. This compares to a net income of $1.1 million, or $0.29 per fully diluted share in the same quarter of 2009. Skystar's adjusted net income for the first quarter of 2010 was $1.4 million, or $0.20 per fully diluted share, compared with $1.0 million, or $0.27 per fully diluted share, in the first quarter of 2009 (See "About Non-GAAP Financial Measures" toward the end of this release). As of March 31, 2010, Skystar had approximately $5.9 million in cash and restricted cash, current assets of $27.1 million and current liabilities of $4.3 million. Fiscal Year 2010 Guidance Revised
Fiscal year 2010 revenue ranges have been revised to $45.5 million to $47.5 million for the full year reflecting partial revenue contribution from two new product dosage forms coming to market. We anticipate the estimated $5 million in total additional revenue to be fully recognized in fiscal 2011. CONFERENCE CALL & WEBCAST INFORMATION
Skystar will host a conference call at 8:00 a.m. ET on Tuesday, May 18, 2010 to review the Company's first quarter financial and operational performance. Mr. Weibing Lu, Skystar Bio-Pharmaceutical chairman and chief executive officer, will host the call, which will be webcast live. The webcast will be made available on the investor relations section of the Skystar corporate website at http://www.skystarbio-pharmaceutical.com. Telephone access to the conference call will also be available in North America by dialing +1 (877) 407-9210 or internationally by dialing +1 (201) 689-8049. An audio replay of the conference call will be available approximately two hours following the conclusion of the call and for the following 30 day period. To access the replay in North America, dial +1 (877) 660-6853, or when calling internationally, dial +1 (201) 612-7415, using replay account code # 286 and conference ID # 350967. An archived replay of the conference webcast will also be available on the investor relations section of the Skystar corporate website at http://www.skystarbio-pharmaceutical.com. To be added to the Company's email distribution for future news releases, please send your request to skystar@grayling.com. About Skystar Bio-Pharmaceutical Company
Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 170 products. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com. About Non-GAAP Financial Measures This press release contains non-GAAP financial measures for the change in the fair value of the Company's warrants. The Company believes that these non-GAAP financial measures are useful to investors because they exclude non-cash charges that our management excludes when it internally evaluates the performance of the Company's business and makes operating decisions, including internal budgeting, and performance measurement, because these measures provide a consistent method of comparison to historical periods. Moreover, management believes these non-GAAP measures reflect the essential operating activities of Skystar. Accordingly, management excludes the change in the fair value of the Company's warrants when making operational decisions. The Company believes that providing the non-GAAP measures that management uses to its investors is useful to investors for a number of reasons. The non-GAAP measures provide a consistent basis for investors to understand the Company's financial performance in comparison to historical periods. In addition, it allows investors to evaluate the Company's performance using the same methodology and information as that used by our management. Non-GAAP measures are subject to inherent limitations because they do not include all of the expenses included under GAAP and because they involve the exercise of judgment of which charges are excluded from the non-GAAP financial measure. However, our management compensates for these limitations by providing the relevant disclosure of the items excluded. Financial Tables Follow The following table provides the non-GAAP financial measure and the related GAAP measure and provides a reconciliation of the non-GAAP measure to the equivalent GAAP measure.
SKBI- Adjusted Net Income
March 31, 2010 March 31, 2009
-------------- --------------
GAAP Net Income 1,096,247 1,064,644
GAAP Basic Earnings Per Share 0.16 0.29
GAAP Diluted Earnings Per Share 0.15 0.29
Additions
Change in fair value of warrants 317,380 (38,328)
-------------- --------------
Total additions 317,380 (38,328)
Non GAAP Net Income 1,413,627 1,026,316
Non GAAP Basic Earnings Per Share 0.20 0.27
Non GAAP Diluted Earnings Per Share 0.20 0.27
Shares used in computing net income per
basic share 7,061,530 3,734,602
Shares used in computing net income per
diluted share 7,140,140 3,734,602
Consolidated Statements of Income and Other Comprehensive Income
(Unaudited)
For Three Months Ended
March 31,
------------------------
2010 2009
----------- -----------
REVENUE, NET $ 4,869,243 $ 3,823,566
COST OF REVENUE 2,291,219 1,946,358
----------- -----------
GROSS PROFIT 2,578,024 1,877,208
----------- -----------
OPERATING EXPENSES:
Research and development 43,995 117,352
Selling expenses 171,134 207,395
General and administrative 619,550 314,695
----------- -----------
Total operating expenses 834,679 639,442
----------- -----------
INCOME FROM OPERATIONS 1,743,345 1,237,766
----------- -----------
OTHER INCOME (EXPENSE):
Other income (expense), net 417 (232)
Interest income (expense), net (4,816) 302
Change in fair value of warrant liability (317,380) 38,328
----------- -----------
Total other income (expense), net (321,779) 38,398
----------- -----------
INCOME BEFORE PROVISION FOR INCOME TAXES 1,421,566 1,276,164
PROVISION FOR INCOME TAXES 325,319 211,520
----------- -----------
NET INCOME 1,096,247 1,064,644
OTHER COMPREHENSIVE LOSS:
Foreign currency translation adjustment (40,816) (38,448)
----------- -----------
COMPREHENSIVE INCOME $ 1,055,431 $ 1,026,196
=========== ===========
EARNINGS PER SHARE:
Basic $ 0.16 $ 0.29
=========== ===========
Diluted $ 0.15 $ 0.29
=========== ===========
WEIGHTED AVERAGE NUMBER OF COMMON SHARES:
Basic 7,061,530 3,734,602
=========== ===========
Diluted 7,140,140 3,734,602
=========== ===========
Consolidated Balance Sheets
ASSETS
March 31, December 31,
2010 2009
------------ ------------
Unaudited
------------
CURRENT ASSETS:
Cash $ 5,911,415 $ 11,699,398
Accounts receivable, net of allowance for
doubtful accounts of $327,857 and $327,857
as of March 31, 2010 and December 31, 2009,
respectively 3,447,078 4,383,187
Inventories 4,996,515 4,074,645
Deposits and prepaid expenses 12,173,047 11,900,314
Other receivables 572,641 490,712
------------ ------------
Total current assets 27,100,696 32,548,256
------------ ------------
PLANT AND EQUIPMENT, NET 10,415,008 8,829,058
CONSTRUCTION-IN-PROGRESS 9,741,767 9,389,120
OTHER ASSETS:
Long-term prepayments 13,276,071 7,980,307
Intangible assets, net 1,768,771 1,860,172
------------ ------------
Total other assets 15,044,842 9,840,479
------------ ------------
Total assets $ 62,302,313 $ 60,606,913
============ ============
LIABILITIES AND CHANGES IN EQUITY
CURRENT LIABILITIES:
Accounts payable $ 421,031 $ 297,567
Other payable and accrued expenses 694,400 917,284
Short-term loans - 220,050
Short-term loans from shareholders 110,025 110,025
Deposits from customers 1,850,051 1,275,958
Taxes payable 825,082 722,106
Shares to be issued to related parties 329,397 327,374
Due to related parties 106,743 185,024
------------ ------------
Total current liabilities 4,336,729 4,055,388
------------ ------------
OTHER LIABILITIES:
Deferred government grant 1,100,250 1,100,250
Warrant liability 510,571 1,538,686
------------ ------------
Total other liabilities 1,610,821 2,638,936
------------ ------------
Total liabilities 5,947,550 6,694,324
------------ ------------
COMMITMENTS AND CONTINGENCIES
CHANGES IN EQUITY:
Preferred stock, $0.001 par value, Nil Series
"A" shares authorized as of March 31, 2010
and December 31, 2009, 48,000,000 Series "B"
shares authorized, Nil Series "B" shares issued
and outstanding as of March 31, 2010 and
December 31, 2009
Common stock, $0.001 par value, 40,000,000 shares
authorized, 7,097,708 and 6,989,640 shares issued
and outstanding as of March 31, 2010 and
December 31, 2009, respectively 7,097 6,989
Paid-in capital 35,966,731 34,580,096
Statutory reserves 3,879,077 3,879,077
Retained earnings 13,671,153 12,574,906
Accumulated other comprehensive income 2,830,705 2,871,521
------------ ------------
Total shareholders' equity 56,354,763 53,912,589
------------ ------------
Total liabilities and shareholders'
equity $ 62,302,313 $ 60,606,913
============ ============
Consolidated Statement of Cash Flows
Unaudited
Three months ended March 31,
----------------------------
2010 2009
------------- -------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $ 1,096,247 $ 1,064,644
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation 123,484 112,930
Amortization 91,370 38,519
Common stock issued for services 16,245 15,052
Common stock to be issued to related
parties for compensation 27,025 -
Bad debt expense - 21,743
Change in fair value of warrant
liability 317,380 (38,328)
Change in operating assets and
liabilities
Accounts receivable 935,790 (994,017)
Inventories (921,558) (2,888,742)
Deposits and prepaid expenses (272,640) 2,551,310
Other receivables (81,901) (9,823)
Accounts payable 123,423 (166,085)
Accrued expenses (223,979) (382,703)
Deposits from customers 573,897 (131,448)
Taxes payable 102,941 900,427
Other payables 1,233 39,916
------------- -------------
Net cash provided by operating
activities 1,908,957 133,395
------------- -------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments of long-term prepayments - (32,233)
Prepayment for potential acquisition (5,499,375) -
Loans to third parties - (366,275)
Purchases of plant and equipment (1,451,016) (73,255)
Payments on construction-in-progress (404,990) (242,507)
------------- -------------
Net cash used in investing
activities (7,355,381) (714,270)
------------- -------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Decrease (increase) in restricted cash (200)
Proceeds from short-term loans - 219,765
Repayment for short-term loans (219,975) -
Repayment to shareholders and directors - (175,812)
Proceeds from shareholders and directors - 83,124
Due (from) to related parties (78,269) -
------------- -------------
Net cash provided by financing
activities (298,244) 126,877
------------- -------------
EFFECT OF EXCHANGE RATE CHANGES ON CASH (43,315) 81,264
------------- -------------
INCREASE (DECREASE) IN CASH (5,787,983) (372,734)
CASH, beginning 11,699,398 576,409
------------- -------------
CASH, ending $ 5,911,415 $ 203,675
============= =============
SUPPLEMENTAL DISCLOSURE OF CASH FLOW
INFORMATION:
Cash paid for interest $ 5,210 $ 19,079
============= =============
Cash paid for income taxes $ - $ -
============= =============
Non-cash investing and financing
activities
Long-term prepayment transferred to
construction-in-progress $ - $ 309,869
============= =============
Long-term prepayment transferred to
property, plant and equipment 439,777 -
============= =============
Construction-in-progress transferred to
property, plant and equipment 52,463 -
============= =============
Cashless exercise of warrants $ 1,345,496 -
============= =============
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
Contact Information: Contacts: Skystar Bio-Pharmaceutical Company Scott Cramer Director -- Director Corporate Development and U.S. Representative (407) 645-4433 Grayling Investor Relations Christopher Chu (646) 284-9426 christopher.chu@grayling.com